Know Your Gabapentinoids

Clinically-grounded explainer on the gabapentinoids: why pregabalin seems to outperform pharmacodynamically-'identical' gabapentin (dosing-equivalence and bioavailability arguments, plus honest self-doubt about clinician bias), and the phenibut puzzle (works better than either baclofen or gabapentin despite being a weaker version of both). Candid about uncertainty ('one of the great mysteries of life'); useful within psych/nootropics circles. Solid Strong.

Quality 65 · Strong. Strong (65): informed, honest, and practically useful, but a fairly niche pharmacology explainer that assembles known mechanisms plus one good dosing-equivalence insight rather than a big-idea contribution.

Claude’s paradigm shift 44 · Moderate. Moderate (44): modest novelty; the dose-nonequivalence hypothesis is a nice reframe but mostly organizes existing pharmacology.

Real-world impact 3 · Moderate. Moderate (3): real influence in the nootropics/psychiatry-reader subculture (phenibut dosing lore, the nootropics survey), vocabulary used by an educated niche.